ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Pre-Mkt 01-05 07:03:09 EST

8.85

-0.18

-1.99%

High9.10	Low8.44	Vol127.42K
Open9.09	D1 Closing9.03	Amplitude7.28%
Mkt Cap592.81M	Tradable Cap330.40M	Total Shares66.98M
T/O1.11M	T/O Rate0.34%	Tradable Shares37.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":8.85,"timestamp":1767387600000,"preClose":9.03,"halted":0,"volume":127418,"delay":0,"floatShares":37332800,"shares":66984661,"eps":-2.294663,"marketStatus":"Pre-Mkt","change":-0.18,"latestTime":"01-05 07:03:09 EST","open":9.09,"high":9.1,"low":8.4422,"amount":1113344.0811400001,"amplitude":0.072846,"askPrice":12.5,"askSize":100,"bidPrice":8.42,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.294663,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767623400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":8.85,"postHourTrading":{"tag":"盘后","latestPrice":8.85,"preClose":8.85,"latestTime":"18:56 EST","volume":368,"amount":3225.37,"timestamp":1767398163000},"volumeRatio":0.3915984938100426},"requestUrl":"/m/hq/s/ENGN/wiki","defaultTab":"wiki","newsList":[{"id":"2593530564","title":"EnGene Fiscal 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530564","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593530564?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:12","pubTimestamp":1766441578,"startTime":"0","endTime":"0","summary":"EnGene  reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $2.10.Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2593458566","title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458566","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458566?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:04","pubTimestamp":1766437483,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of $(0.34) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49549264/engene-holdings-q4-eps-0-73-misses-0-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2593583784","title":"enGene reports FY net loss of USD 117.3 million, more than double year-on-year","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583784?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437403,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. reported its full year  financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7QrwSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593458607","title":"enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458607?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUAKX7C8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593583224","title":"Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583224","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583224?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":"Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ. Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol. enGene selected for FDA's CDRP Program to support CMC readiness. Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028. \"We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved,\" said Ron Cooper, President and Chief Executive Officer. \"With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in prepar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","CMC","LU1363072403.SGD","BK4232","LU2237443895.HKD","LU2746668974.SGD","BK4135","LU0149725797.USD","BK4161","LU0267386448.USD","ENGN","CR","LU0971096721.USD","LU2237443465.HKD","LU2237443622.USD","LU2237443549.SGD","BK4022","R","BCG","LU0170899867.USD","IE00BKVL7J92.USD","LU2746668461.USD","IE00BHPRN162.USD","LU2237443382.USD","TRAE","BK4006","LU2237443978.SGD","BK4139","DDX","IE00BZ1G4Q59.USD","LU0882574139.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2588056337","title":"EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056337","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056337?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:44","pubTimestamp":1764683062,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said Tuesday that the US Food and Drug Administration selected detalimogene for its chemistry, manufacturing and controls development and readiness pilot program.Detalimogene is an inves","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588555320","title":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588555320","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588555320?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:18","pubTimestamp":1764681501,"startTime":"0","endTime":"0","summary":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing ReadinessDec 2 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588058033","title":"enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058033","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058033?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:47","pubTimestamp":1764679656,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. has announced positive preliminary results from the pivotal cohort of its LEGEND trial studying detalimogene voraplasmid  in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer  with carcinoma in situ  with or without concomitant papillary disease. The results showed an improved complete response rate of 62% at six months. Safety data from 125 patients demonstrated a favorable tolerability profile, with low rates of treatment-related adverse events (42%) and dose interruptions . The company has not specified if these results have already been presented at a scientific meeting or will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4149Bc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588676058","title":"enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588676058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588676058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588058972","title":"enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls  Development & Readiness Pilot Pprogram","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058972?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2586535478","title":"enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586535478","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586535478?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073816,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. Chief Strategy and Operations Officer Alex Nichols, Ph.D., is scheduled to deliver the presentation, which will be accessible via webcast on the enGene website and archived for 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6xsmTn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4139","BK4127","ENGN"],"gpt_icon":0},{"id":"2584924674","title":"enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924674","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924674?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573315,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - enGene Holdings Inc ::*ENGENE HOLDINGS FILES FOR OFFERING OF COMMON SHARES, SIZE NOT DISCLOSED - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:55:30 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDb5dKf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583055325","title":"enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583055325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583055325?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:21","pubTimestamp":1763122901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nFWN3WQ169:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583065095","title":"enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583065095","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583065095?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:21","pubTimestamp":1763119319,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) is drawing attention after announcing positive preliminary results from the pivotal cohort of its Phase 2 LEGEND trial. The data showed a high complete response rate and a favorable safety profile in challenging bladder cancer cases.\nSee our latest analysis for enGene Holdings.\nenGene Holdings’ impressive momentum really kicked in after its recent LEGEND trial data sent the stock soaring, highlighted by a 40% seven-day share price return and a staggering 129% gain over...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/engene-holdings-engn-valuation-in-focus-following-promising","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/engene-holdings-engn-valuation-in-focus-following-promising","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","ENGN","BK4139"],"gpt_icon":0},{"id":"2583807595","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Expected Economic Data Gaps","url":"https://stock-news.laohu8.com/highlight/detail?id=2583807595","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583807595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:57","pubTimestamp":1763042229,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% lower in Thursday's premarket activity as investors weighed th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"70eb9cd7cf3b474dd15e72f3f7c2341c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","VDC","XLV","ARX","VHT.AU","EETH","VIS","FAZ","RTH","ARX.AU","UNG","IYK","IGV","RTH.AU","XLI","BETH","DDS","SPY","XLY","IVV","EQR","VHT","SOXX","SPY.AU","ENGN",".DJI","EEM","BITO","IYE","USO","IYH","CSCO","XRT",".IXIC","XLK","XLF","TTE","BWEN","IYJ","XLE","XSD","IYW","XLP","PMR","FAS","IGM"],"gpt_icon":1},{"id":"2583523395","title":"EnGene Prices $130 Million Offering of Common Shares, Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2583523395","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583523395?lang=en_us&edition=fundamental","pubTime":"2025-11-13 16:37","pubTimestamp":1763023020,"startTime":"0","endTime":"0","summary":"EnGene  said Thursday it priced an underwritten public offering of 12.6 million shares at $8.50 per share and pre-funded warrants to purchase 2.7 million shares at $8.4999 per warrant for total expected gross proceeds of $130 million.The underwriters were granted a 30-day option to purchase up to 2.3 million additional shares.Closing of the offering is expected to occur on or about Friday, subject to customary closing conditions, the company said.Shares were 4.2% lower in premarket trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583537820","title":"BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583537820","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583537820?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:28","pubTimestamp":1763011713,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per ShareNov 13 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS INC  -  PRICING OF 12,558,823 COMMON SHARES AT A PUBLIC OFFERING P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WO1N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583553782","title":"enGene Holdings Inc  -  Pricing of 12,558,823 Common Shares at a Public Offering Price of $8.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583553782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583553782?lang=en_us&edition=fundamental","pubTime":"2025-11-13 13:27","pubTimestamp":1763011660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WO1N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2583053104","title":"Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583053104","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583053104?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:29","pubTimestamp":1762997381,"startTime":"0","endTime":"0","summary":"enGene Holdings recently reported additional preliminary efficacy data from its pivotal Phase 2 LEGEND trial for detalimogene voraplasmid in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer, along with a protocol amendment changing the primary clinical endpoint after discussions with the FDA.\nThis update reveals that earlier patients in the study experienced a lower 12-month complete response rate compared to FDA-approved therapies, leading to significant...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/could-a-shift-in-engene-engn-trial-endpoints-reveal-new-prio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-holdings/news/could-a-shift-in-engene-engn-trial-endpoints-reveal-new-prio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2583581618","title":"EnGene Launches Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581618","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581618?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:53","pubTimestamp":1762988026,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said late Wednesday it launched an underwritten public offering of common shares.The company plans to offer underwriters a 30-day overallotment option to buy up to an additional 15% of the shares offered, according to a statement.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":-0.0684},{"period":"1month","weight":0.1062},{"period":"3month","weight":0.1419},{"period":"6month","weight":1.3289},{"period":"1year","weight":0.2535},{"period":"ytd","weight":-0.0199}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction